Oncolytic virus therapy has recently been recognized as a promising new therapeutic approach for cancer treatment. In this study, we are proposing for the first time to evaluate the in vitro and in vivo oncolytic capacities of the Cowpox virus (CPXV). To improve the tumor selectivity and oncolytic activity, we developed a thymidine kinase (TK)-deleted CPXV expressing the suicide gene FCU1, which converts the non-toxic prodrug 5-fluorocytosine (5-FC) into cytotoxic 5-fluorouracil (5-FU) and 5-fluorouridine-5 0 -monophosphate (5-FUMP). This TKdeleted virus replicated efficiently in human tumor cell lines; however, it was notably attenuated in normal primary cells, thus displaying a good therapeutic index. Furthermore, this new recombinant poxvirus rendered cells sensitive to 5-FC. In vivo, after systemic injection in mice, the TK-deleted variant caused significantly less mortality than the wild-type strain. A biodistribution study demonstrated high tumor selectivity and low accumulation in normal tissues. In human xenograft models of solid tumors, the recombinant CPXV also displayed high replication, inducing relevant tumor growth inhibition. This anti-tumor effect was improved by 5-FC co-administration. These results demonstrated that CPXV is a promising oncolytic vector capable of expressing functional therapeutic transgenes.
INTRODUCTION
Recent advances in the molecular biology of cancer have led to the development of novel therapeutic agents, including viruses that destroy cancer by lytic viral replication. This approach has been termed viral oncolysis, and several recent studies have demonstrated the successful application of oncolytic viruses (OVs) as effective therapeutics to tumors that have become resistant to conventional chemotherapy. 1 The acceptable safety and tolerability of various OVs (herpes simplex virus, vaccinia virus, adenovirus, reovirus, parvovirus, measles virus, and Newcastle disease virus) in patients have also been demonstrated. 2 In 2015, the U.S. Food and Drug Administration (FDA) approved the first oncolytic virus Imlygic (talimogene laherparevec, also known as T-VEC) for local treatment of patients with recurrent melanoma. 3 The genome organization, lysis capacity, and wide tumor tropism of vaccinia virus, the most commonly used poxvirus vector for cancer therapy, 4, 5 make it an ideal oncolytic agent for cancer treatment. The lead product JX-594 (Pexa-Vec) has demonstrated effective results in many clinical trials. 6 The vaccinia phylum includes many strains differing by their antitumor potency as well as the frequency of associated viral complications. 7 In the perspective of finding attenuated Vacinia virus (VACV) variants, several gene deletions have been tested. 8, 9 Other members of the Poxviridae family have been studied for their potential oncolytic properties, such as Myxoma virus, 10 Yaba-like disease virus, 11 ORF virus, 12 and Raccoonpox virus 13 and have shown encouraging results in terms of safety and in vitro efficacy in preclinical studies.
In this article, we characterized another member of the Poxviridae family, the Cowpox virus (CPXV), as a putative new oncolytic virus.
CPXV is a European close variant of VACV that belongs to the genus Orthopoxvirus (OPV) of the Poxviridae family. CPXV is described as the source of the first vaccine used by Edward Jenner, who provided the first scientific description of vaccination by detailing the efficacy of CPXV scarification in inducing protective immunity against challenge with variola virus. 14, 15 CPXV has a broad host range and is believed to persist in a reservoir comprising various rodents (particularly voles and wood mice) indigenous to parts of Europe and Asia. 16 Human CPXV infections are sometimes acquired from cows, sheep, and rodents, 17 but the domestic cat is responsible for the majority of these human CPXV cases. 18, 19 In humans, the pathogenicity of CPXV is very limited because cowpox is generally a selflimited disease. 20 Infection is usually relatively benign in immunocompetent individuals and treatment is largely supportive. [21] [22] [23] Human-to-human transmission of Cowpox has never been reported.
In contrast to other double-stranded DNA viruses, poxviruses encode their own DNA replication and transcription machinery and are able to replicate in the cytoplasm, avoiding the risk of integration into the host genome. Among Orthopoxvirus species, CPXV have the largest genome, averaging above 220 kbp, about 30 kbp larger than the VACV genome. CPXV grows in vitro in monkey cells under similar conditions as VACV. Visible plaques are formed in approximately 1 to 2 days on Vero cells. CPXV is able to infect human cells, as described in several clinical cases, [24] [25] [26] including epithelial cells, fibroblasts, and macrophages in vivo. 27 Several publications mentioned the use of human tumoral cell culture for the amplification of CPXV. 28, 29 Until now, the oncolytic potential of this virus had not been described.
Like the other members of the Orthopoxviridae family, CPXV possesses essential characteristics of use in virotherapy: an easily modifiable genome that offers the possibility to insert large therapeutic foreign genes, no risk of genomic integration, ability to replicate in human cells, rapid lytic cycle, and no pre-immunity that might hinder vector replication. Consequently, we hypothesized that CPXV could be an ideal alternative platform for oncolytic virotherapy.
Armed oncolytic vectors are widely used in current clinical trials. 30 In a previous study, we described a target tumor cell killing strategy by associating an oncolytic vaccinia virus deleted in thymidine kinase (TK), combined with a suicide gene therapy. 31 The TK-deleted VACV expressing the FCU1 fusion suicide gene, combined with the administration of the 5-fluorocytosine (5-FC) prodrug, displayed a highly potent anti-tumor effect both in vitro and in vivo.
In this study, we have explored the feasibility of this approach using CPXV as a viral vector and thus constructed a CPXV armed with the FCU1 gene. The FCU1 gene was inserted into the TK locus of the CPXV genome under the control of the strong p11k7.5 promoter.
In vitro, we assessed the ability of the recombinant CPXV virus to replicate and kill various human tumor cell lines. We also evaluated the behavior of the virus on human primary cells.
We further examined the safety profile, biodistribution, and antitumor effect of this TK-deleted virus in vivo. We demonstrated here that CPXV possesses the features of a good oncolytic platform, amenable to arming with therapeutic transgenes.
RESULTS

Virus Engineering
CPXV shares with VACV an essential characteristic of OVs: a large easily modifiable genome, especially with homologous recombination protocol. Due to this high homology between the two viruses (78.5% of genome identity) and particularly in the TK region (97.4% identity), a VACV shuttle plasmid was used to create the CPXtk À /gfp::fcu1
vector. Genomic structures of wild-type and recombinant CPXVs (CPXtk À /gfp::fcu1 expressing the GFP::FCU1 fusion gene) are shown in Figure 1A . The coding sequence of GFP-FCU1 (GFP::FCU1) fusion was introduced into the TK locus under transcriptional control of the synthetic vaccinia promoter p11k7.5, as described in the Materials and Methods. This chimeric GFP::FCU1 gene was generated by directly fusing in frame the coding sequences of eGFP and FCU1, followed by a precise deletion of the translation stop and start codons of eGFP and FCU1, respectively. This GFP::FCU1 fusion protein exhibits cytidine deaminase (CDase) and uracil-phosphoribotransferase (UPRTase) activities similar to those of the FCU1 protein. This chimeric protein displays a fluorescent signal intensity equivalent to the one of native eGFP protein (P.E., unpublished data).
Expression of the GFP::FCU1 fusion protein was confirmed by western blot using the mouse monoclonal antibody directed against FCU1 ( Figure 1B ). Western blot showed the expected band at 72 kDa for GFP::FCU1 protein.
Analysis of the FCU1 Enzymatic Assays and Bystander Effect
Expression of functional FCU1 by CPXtk À /gfp::fcu1 was confirmed by quantification of the enzymatic activities of FCU1. The CDase As shown in Table 1 , elevated CDase activity was found in cells infected with CPXtk À /gfp::fcu1, whereas no CDase activity was detectable in mock or CPXwt-infected cells. In the same way, UPRTase activity was only found in cells infected by the recombinant CPXV.
A major strength of any prodrug activation model is the potential act on neighboring untransfected cells, after diffusion of the cytotoxic drug. In the case of FCU1/5-FC combination, an efficient bystander effect has been reported because 5-FU is highly diffusible around the replication site of the oncolytic virus. To evaluate the ability of CPXV to enter and replicate in human tumor cell lines, we measured the level of viral particles after 72 hr of infection in various cell lines (Figure 2A ). The CPXtk À /gfp::fcu1 virus was able to infect and replicate in all the tumor cell lines tested. However, these results highlighted a cell-line-dependent heterogeneity of replication. High replication was observed in HCT116 cells, where CPXtk À /gfp::fcu1 viral replication reached a 100,000-fold increase ( Figure 2A ), and lower amplification was shown in OE19, Hep G2, and Capan-2 cells, with 1,400-, 1,800-, and 2,700-fold increases, respectively.
Nevertheless, antitumoral activity assays confirmed that CPXtk À / gfp::fcu1 was able to infect and kill all tested tumor cell lines with a dose-dependent effect ( Figure 2B ). Hep G2 cell viability after infection with CPXtk À /gfp::fcu1 varied from 95% at an MOI of 0.0001 to 2% at a MOI of 0.1. Furthermore, CPXtk À /gfp::fcu1 showed an efficient anti-tumor activity on A549 (lung carcinoma) and U-87 MG (glioblastoma) cells with less than 25% viability at a low MOI (0.0001).
Cell Killing by Combination of Prodrug Activation with Viral Oncolysis
In order to compare the antitumoral activity of CPXtk These results indicate that recombinant CPXtk À /gfp::fcu1 acquired an enhanced in vitro anti-tumor activity as compared to CPXwt virus in the presence of 5-FC prodrug.
Pathogenicity Evaluation In Vitro and In Vivo
Phenion full thickness is a 3D multilayered skin equivalent that simulates histological and physiological properties of human skin. The model represents a multilayered epidermis and a dermal compartment. 33, 34 The pathogenesis of several different virus infections, including papillomaviruses, adenoviruses, parvoviruses, poxviruses, and herpesviruses was tested with 3D skin substitutes. 35, 36 In the case of poxviruses, especially CPXV, it has already been demonstrated that epithelial raft culture can be used as a predictive model for pox lesions. 37 In our experiment ( Figure 2C ), we evaluated the replication of both CPXwt and the TK-deleted virus. After 7 days of infection, CPXtk À /gfp::fcu1 reached lower titers than the CPXwt (<30-fold and 833-fold amplifications, respectively). These results confirmed the benefit of deleting TK gene for safety improvement.
We also demonstrated that human peripheral blood mononuclear cells (hPBMCs) were weakly infected by our TK-deleted CPXV and that the virus was not able to replicate in these primary cells. As shown in Figure 2D , after 16 hr of infection, CPXtk À /gfp::fcu1 penetrated poorly into PBMCs, with less than 5% of cells infected at MOI 1 and no viral amplification observed 4 days post infection. The replication of the recombinant CPXV was totally abortive in these blood cells: CPXtk À /gfp::fcu1 had a negligible impact on these cells. In vivo, the virulence of CPXV was assessed in immunocompetent BALB/c mice. Animals were injected intravenously (i.v.) with CPXwt or CPXtk À /gfp::fcu1 at a dose between 1 Â 10 4 and 1 Â 10 7 particle forming units (pfu)/mouse ( Figure 4A ). Weight loss, mortality, and side effects were monitored for more than 60 days. As expected, considering mice as the natural reservoir of the virus, the CPXwt demonstrated a high and rapid toxicity after injection at the highest dose (1 Â 10 7 pfu), with 90% mortality 1-day post injection. At 10 6 pfu, we still observed a high mortality, but with a delay in the time to death (90% mortality 24 days post infection). At lower doses (10 5 and 10 4 pfu), no mortality was observed but mice infected with CPXwt exhibited pock lesions around the genital area, footpad, and mouth. These side effects appeared 9 days post-infection and persisted until the end of the experiment.
In comparison, the recombinant CPXtk À /gfp::fcu1 virus was significantly attenuated. All treated mice remained healthy, with no weight loss (data not shown). At the doses of 10 6 and 10 7 pfu, pock lesions were detected on the tail and face of the mice. In contrast to pock lesions induced by CPXwt, these mild and self-limiting lesions healed in approximately 20 days. No clinical signs of illness were observed at the lowest doses.
Biodistribution of CPXtk -/gfp::fcu1 and Detection of FCU1
Protein in Tumors
As an in vivo demonstration of the tumor selectivity of CPXtk À / gfp::fcu1 replication, Swiss nude mice bearing subcutaneous (s.c.) U-87 MG human glioblastoma xenograft tumors were treated with CPXtk À /gfp::fcu1 via the i.v. route. Viral titers were determined by a standard plaque assay on Vero cells.
A significant difference between infectivity of tumor and normal tissue was observed 2 days after inoculation of the virus ( Figure 4B ). CPXtk À /gfp::fcu1 was only detected in tumors. 7 days after injection, CPXtk À /gfp::fcu1 viral particles had titers 100-fold or higher in tumor tissues compared to any other organ tissue tested, including the brain, bone marrow, kidneys, liver, ovaries, blood, and spleen. Low amounts of virus were detected in the skin (with the highest level at 30 pfu/mg of tissue), lymph nodes, and, to a smaller extent, in the lung (with less than 1 pfu/mg of tissue). The titration of CPXtk À / gfp::fcu1 in the entire tumor at day 7 after a single injection of 1 Â 10 6 pfu revealed a viral load of up to 7 Â 10 6 pfu, demonstrating that CPXV was able to reach and fully replicate in the tumor after systemic injection.
The presence of CPXV and the expression of GFP::FCU1 gene into the tumor was analyzed by immunostaining in LoVo human colorectal tumor-bearing mice treated intratumorally (IT) by the recombinant CPXV vector. FCU1 and viral immunostaining were performed 5 days after virus administration. Fluorescence microscopy of tumor sections confirmed the expression of FCU1 ( Figure 4C1 ) and the presence of viral proteins ( Figure 4C2 ). As expected, the distribution of the FCU1 fusion protein correlated with the area of virus detection ( Figure 4C3 ). Virus was detected in almost all the tumoral mass, showing that CPXV was able to replicate and rapidly invade the tumor. The merge picture clearly showed the spread of the virus and a strong expression of the therapeutic FCU1 protein ( Figure 4C3 ). In the U-87 MG glioblastoma model, as shown in Figure 5A , CPXV treatment resulted in the stabilization of the tumor growth, with a reduction of more than 70% of tumoral mass as compared to the control group (p < 0.0005). This strong tumor growth inhibition was also improved by the addition of 5-FC that led to an additional but not significant tumor size reduction of 10% as compared to CPXV alone. In this U-87 MG glioblastoma model, mice showed classic signs of illness (mainly diarrhea and weight loss) after 5 days of 5-FC treatment, presumably due to 5-FU toxicity. These side effects were reversible upon 5-FC treatment discontinuation.
A single IT injection of CPXV in the LoVo colorectal model tumor ( Figure 5B ) resulted in a weak antitumoral effect in comparison to the control group (p > 0.05). The administration of 5-FC alone had no effect on tumor growth. The lack of antitumoral activity of the virus alone was compensated by 5-FC treatment, which demonstrated improved efficacy, resulting in approximately 60% tumor regression after 60 days (p < 0.05). In this LoVo model, in contrast to the U-87 MG model, no 5-FU-related toxicity was observed. Consequently, a second cycle of 5-FC treatment was administered to the mice. 
DISCUSSION
The data presented in this article underscore the interest of using CPXV as a new platform for vaccine delivery. In this study, the virus ability to control cellular proliferation was notable in all the tested human tumor cell lines. The most remarkable results were obtained using HeLa and Hep G2 cells, in which cell proliferation was reduced by 85% following CPXV treatment at a MOI of 0.01. Equally impressive, HCT116 colon carcinoma cell proliferation was totally inhibited at the same multiplicity of infection, confirming the strong oncolytic potential of CPXV. Our data demonstrated that CPXV is able to infect and replicate in a number of human tumor cell lines and it is also able to kill them.
Nevertheless, complete infection and lysis of the whole tumor is difficult. Therefore, oncolytic viruses are often armed. One example of arming is enzyme-prodrug systems, which are capable of exerting a strong bystander effect and which may enhance the oncolytic efficacy of the virus therapy by eliminating surrounding uninfected tumor cells. The FCU1/5-FC enzyme-prodrug system has been extensively investigated in vitro and in preclinical models of xenografts in using a variety of delivery systems, including replication-defective viruses 32,38 and replication-selective oncolytic viruses. 31, [39] [40] [41] [42] [43] The proof of this suicide gene concept has also been demonstrated in humans using TG4023, a non-propagative Vaccinia virus (MVA) hosting the FCU1 gene. 44 In this phase I study, after a single percutaneous IT injection of TG4023 in primary or metastatic liver tumors in combination with systemic administration of 5-FC, therapeutic 5-FU concentrations in tumors were detected without significant systemic exposure to the cytotoxic anticancer drug.
The expression of the fusion gene GFP::FCU1 in the CPXV backbone allows infection and replication monitoring of the virus and of the enzymatic activation of the 5-FC prodrug by the bifunctional suicide protein FCU1. The FCU1 gene, through its expression by CPXtk À / gfp::fcu1, was able to convert non-toxic prodrug 5-FC into cytotoxic 5-FU and 5-FUMP. The produced 5-FU diffuses in and out of cells and does not require cell-to-cell contact for cell toxicity. This bystander effect enhances the antitumor efficacy of the VDEPT approach by eliminating surrounding uninfected tumor cells via in situ production of cytotoxic 5-FU. 45 In a human colorectal cancer in vitro model, the recombinant CPXtk À /gfp::fcu1 vector exhibited less than 10% of cytotoxicity, but reached more than 90% cytotoxicity upon addition of 5-FC and production of 5-FU in the culture media. In our recombinant CPXV, the expression of the transgene is under control of the early/late p11k7.5 VACV synthetic promoter. The use of a vaccinia promoter in a Cowpox vector was already demonstrated by the expression of marker genes (eGFP and mRFP) under early and late vaccinia promoter. 46 Moreover, we previously demonstrated the superiority of p11k7.5 compared to natural p7.5 and pH5R VACV promoters for gene expression in the MVA backbone. 38 In our study, the efficacy of the p11k7.5 synthetic promoter in the cowpox context was largely confirmed by western blot analysis, showing a strong expression of the FCU1 therapeutic gene in a human cancer cell line.
These results were confirmed in vivo by imaging: the IT administered recombinant CPXtk À /gfp::fcu1 vector invaded the tumor tissues and the FCU1 protein was correctly and largely expressed in the tumor. Moreover, the IT injection resulted in a significant reduction of the tumor progression, with or without 5-FC administration. Indeed, we showed here that CPXV replicated in the glioblastoma xenograft model and rapidly killed tumoral cells, demonstrating a potent antitumor efficacy due to viral replication in the tumor. In a model more resistant to viral replication, like Lovo colorectal cancer, the expression of the therapeutic transgene is particularly beneficial. In this model, the recombinant virus alone had weak antitumoral activity, whereas the concomitant 5-FC treatment led to significant inhibition of tumoral growth. However, this setting can still be optimized. It might also be possible, in order to increase the efficacy of the combination and reduce side effects to extend the viral injection/5-FC treatment interval and dose. Numerous schedules of administration could also be evaluated, starting with the route of injection. In our study, the single injection of the recombinant CPXV at 1 Â 10 6 pfu by i.v. failed (data not shown).
Our hypothesis is that a too low dose was injected. Indeed, we know, thanks to a biodistribution experiment, that virus injected by a systemic route is able to reach the tumor. Another possibility could be to maintain the same dose, but with two or three injections. All these regimens require further investigations.
We then demonstrated in a series of experiments that inactivation of the TK gene leads to very low levels of virus multiplication in an in vitro skin model as well as attenuation in mice, presumably due to restricted multiplication in non-dividing cells. In an immunocompetent mouse model, a natural CPXV host, 16 TK-deleted CPXV was significantly attenuated compared to wild-type CPXV. Unlike CPXwt, no mortality was observed in mice infected by CPXtk À / gfp::fcu1 during the study and only few reversible skin side effects were identified. Moreover, we demonstrated the ability of the recombinant CPXV to specifically replicate in implanted tumors after i.v. injection while leaving, apart from skin and nodes, most organs unaffected.
In order to further decrease CPXV-associated side effects, one or multiple gene deletions could be considered. Xu et al. 46 demonstrated that 10 genes are involved in CPXV virulence by the induction of hemorrhagic lesions on chorioallantoic membranes. The deletion of the CrmA gene from cowpox had also demonstrated some attenuation in the mouse pulmonary disease model. 47 Moreover, CPXV like VACV encodes a large number of immunomodulatory proteins involved in the inhibition or evasion to the host inflammatory and immune responses 29, 48 in antiapoptotic proteins (F1L, N1L, and E3L) or proteins acting as growth-stimulating factors like VGF. 49, 50 Deletion of these genes could improve the tumoral selectivity and safety profile of CPXV, as demonstrated with VACV. 51, 52 Interestingly, CPXV harbors the most complete set of open reading frames expected to encode immune evasion proteins that collectively target a wide range of antiviral host responses. 53, 54 Unlike VACV, CPXV prevents stimulation of CD8+ T cells, and this correlated with retention of MHC-I in the endoplasmic reticulum by the CPXV203 protein. 55 This particular skill allows CPXV to hide from the immune system. Studies highlighted that CPXV and VACV are clearly distinguishable 56 and not immunologically identical. 57 Yet sporadic human CPXV infections have been more frequent in recent years than in the past, probably due to the cessation of VACV-based, smallpox vaccination. 25, [58] [59] [60] Several studies highlight that VACV vaccination protects against CPXV challenge, although to a different degree, depending on the severity of the challenge. 61 These results on animals seem to be confirmed in humans because recent vaccination with VACV, in fact, does not fully protect against Cowpox; 60 no or limited neutralizing antibodies are produced. In this context, the possible development of CPXV as a new or second wave in the setting of OV-based treatment requires further investigations. Another hypothesis, related to the emergence of human CPXV infection, is the diversity of CPXV strains. 62, 63 Screening different strains as oncolytic viruses would be of definite interest. In summary, this study represents, to our knowledge, the first characterization of an oncolytic CPXV and its use as a vector for VDEPT. Considering these results and the CPXV characteristics (cytoplasmic replication, high titer production, easily modifiable genome with high capacity of insertion, and ability to escape innate and acquired immunity), CPXV could become an ideal vector candidate for oncolytic viral therapies.
MATERIALS AND METHODS
Cell Lines
Human CPXwt and CPXtk À /gfp::fcu1 vector were grown on HeLa cells and purified on a sucrose gradient. Virus stocks were titrated on Vero cells by plaque assay. Viruses were adsorbed on cell monolayers for 30 min at 37 C. Infected cells were incubated in fresh medium supplemented with 5% FCS and 1% agar at 37 C in a 5% CO 2 atmosphere. After 72 hr, the infected cells were stained with a second agar overlay supplemented with 0.008% neutral red.
Western Blotting
LoVo tumor cells were infected by CPXwt and CPXtk À /gfp::fcu1 at a MOI of 0.1 and incubated for 24 hr. Cell lysate proteins (30 mg as determined by using a Bio-Rad protein assay) were run on a 10% SDS-PAGE gel under reducing conditions and transferred onto a nitrocellulose membrane. The membrane was incubated with anti-FCU1 mouse monoclonal antibody 3H1 31 and washed and incubated with anti-mouse secondary antibody coupled to horseradish peroxidase (Amersham, Les Ulis, France). Detection was done using enhanced chemiluminescence (Amersham).
Enzymatic Assays
CDase and UPRTase activities in LoVo cells were determined using 38 Briefly, 5-FC, 5-FU, and 5-FUMP were isocratically separated using HPLC (supelcosil LC-18-S column and UV detection at 260 nm and 280 nm). For detection of CDase activity, the mobile phase was 50 mM phosphoric acid adjust to pH 2.1 with ammonium hydroxide. For detection of UPRTase activity, the mobile phase was 20 mM KH 2 PO 4 , 5 mM tetrabutylammoniumsulfate, and 5% methanol adjusted to pH 5 with potassium hydroxide.
CDase activity was also quantified by measuring the amount of 5-FU released in the culture media. LoVo cells were infected with the different vectors at a MOI of 0.0001 and plated in a 6-well culture dish (1 Â 10 6 cells/well). After 48 hr, 1 mM 5-FC was added to the culture medium. Every day for 1 week, 5-FC and 5-FU concentrations in the media were measured by HPLC. 50 mL of media were quenched with 1 mL of ethyl acetate/2-propanol/0.5 M acetic acid solution (84:15:1). The samples were vortexed and centrifuged. The organic supernatant was evaporated to dryness and reconstituted in 50 mL of water and analyzed by HPLC using a mobile phase of 50 mM phosphoric acid adjusted to pH 2.1. Results are expressed as the percentage of 5-FU relative to the total amount of 5FC + 5FU after various incubation times with 5-FC. by scarification of the tissue. Cultures were incubated for 7 days at 37 C and medium was changed every other day. Viral replication both in medium and skin was quantified on Vero cells by plaque assay after 2 cycles of sonication in PBS. 4 pfu to 1 Â 10 7 pfu, were injected intravenously in the tail vein. The animals were examined daily throughout the course of the experiment for signs of illness, weight loss, general appearance, and pock lesion formation.
Subcutaneous Tumor Models
Female Swiss nude mice were obtained from Charles River Laboratories. Animals used in the studies were uniform in age (6 weeks) and body weight (20-23 g ).
Mice were injected s.c. into the right flank with 5 Â 10 6 human tumor cells (LoVo or U-87 MG). When tumors reached a diameter of 100-300 mm 3 , mice were assigned in a random, blinded manner to receive the recombinant or wild-type virus.
Biodistribution of the Recombinant CPX Virus
The presence of CPXtk À /gfp::fcu1 virus in tumors and organ samples was evaluated by virus titration. The virus was injected i.v. at the dose of 1 Â 10 6 pfu through tail vein into female nude mice bearing s.c. U-87 MG tumor. Mice were sacrificed 2 and 7 days post infection. Mice were perfused intracardially with an exsanguinating solution (0.9% NaCl with heparin 50 IU/mL) until blood was removed. Tumors and organs were then collected, weighed, homogenized in PBS, and sonicated. Viral titers were quantified by plaque assay on Vero cells and standardized per milligram of tissue.
In Vivo Antitumor Activity of the Recombinant CPX Virus in Subcutaneous Tumor Model Nude mice bearing established s.c. implanted U-87 MG or LoVo tumors were treated by IT injection of CPXtk À /gfp::fcu1 vector at the dose of 1 Â 10 6 pfu (in 100 mL of PBS) or vehicle (control group). 5 days post-virus or vehicle injection, 5-FC was administered by oral gavage at 100 mg/kg (0.5 mL of 5-FC 0.5% in water) twice a day for 3 weeks. Tumor size was measured twice a week using calipers. Tumor volume was calculated in mm 3 using the formula (P/6)(length Â width 2 ).
Immunohistochemistry
Detection of FCU1 and the viral proteins was performed by immunohistochemical labeling. For each treatment, 3 slides were analyzed. 5 days after IT injection of CPXtk À /gfp::fcu1 at the dose of 1 Â 10 6 pfu, resected LoVo tumors were fixed with 4% formaldehyde in 0.1 M phosphate buffer. Tumors where then desiccated and embedded in paraffin wax. Sections (5 mM) were mounted on adhesive glass slides and used for histological analysis.
Detection of FCU1 protein was performed by immunostaining of the slides fixed with tumor with anti-FCU1 mouse monoclonal antibody 3H1, followed by Goat anti Mouse-immunoglobulin-G (IgG)-Polymer Dextran HRP (DAKO, K4001) (red staining). CPXV-infected cells were detected upon incubation of the slide with rabbit IgG anti vaccinia-virus (B 65101R, Biodesign, dilution 1/1,000), followed by goat anti-rabbit IgG-Polymer Dextran HRP (DAKO, K4003, dilution 1/1,000) (green staining). To block non-specific antibody binding, slides were incubated 30 min with Linblock solution between the two staining steps. Coverslips were counterstained with DAPI (B-2883 SIGMA) (blue staining) and mounted on glass slides. Negative control tumors also underwent the same immunostaining treatment for comparison purposes. Slides were analyzed using Nikon microscopy.
Statistical Analysis
Statistical analyses of tumor volumes were performed using the nonparametric Mann-Whitney U test and the log-rank test was applied for statistical survival analysis (Statistica 7.1 software, StatSoft). A p value < 0.05 was considered to be statistically significant and is represented by stars on the figures.
